Research Paper Volume 13, Issue 2 pp 2959—2981

A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma

KM curve of OS of patients stratified by age, stage, recurrence, and current tumor status by five-lncRNA signature. (A) KM curves of the elder patients’ group and (E) KM curves in the younger patients’ group; (B) KM curves in the advanced-stage patients' group and (F) KM curves in the earlier-stage patients' group. (C) KM curves in the recurrence patients’ group and (G) KM curves in the no recurrence patients’ group. (D) KM curves in the with tumor patients’ group and (H) KM curves in the tumor-free patients’ group.

Figure 4. KM curve of OS of patients stratified by age, stage, recurrence, and current tumor status by five-lncRNA signature. (A) KM curves of the elder patients’ group and (E) KM curves in the younger patients’ group; (B) KM curves in the advanced-stage patients' group and (F) KM curves in the earlier-stage patients' group. (C) KM curves in the recurrence patients’ group and (G) KM curves in the no recurrence patients’ group. (D) KM curves in the with tumor patients’ group and (H) KM curves in the tumor-free patients’ group.